Ketim Technologies Marks One-Year Anniversary with Breakthrough in Postpartum Depression Biomarker Discovery
Brisbane, Australia – April 16, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has marked its first anniversary with significant scientific progress and growing investor interest in its pioneering approach to early detection of postpartum depression (PPD).
Ketim Technologies Selected for AusBiotech Innovation Activation Program
Brisbane, Australia – April 3, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has been selected to join AusBiotech’s inaugural Innovation Activation Program, delivered as part of the Australian Government’s Industry Growth Program.
Ketim Technologies CEO Presents on Precision Medicine for Mental Health at Translational Research Institute Seminar
Brisbane, Australia – March 21, 2025 – Ketim Technologies, a pioneer in biomarker-based diagnostics for perinatal mental health, is proud to share that Founder and CEO, Dr. Clarissa Yates, Ph.D., presented at the Power Up Your Multi-Omic Discoveries | Next Gen Olink® Proteomics seminar, hosted by the Australian Genome Research Facility (AGRF Ltd) at the Translational Research Institute, Brisbane.
Ketim Technologies CEO Shares Lived Experience on Birth Trauma and Mental Health at PSANZ 2025
Brisbane, Australia – March 16, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to share that Founder and CEO, Dr. Clarissa Yates, Ph.D., participated as a panelist at the Perinatal Society of Australia and New Zealand (PSANZ) 2025 Breakfast Symposium, Beyond Birth: Compassionate Care after Birth Trauma and its Relationship with Mental Health Care.
Ketim Technologies CEO Shares Capital Raising Insights at International Women’s Day Event
Brisbane, Australia – March 5, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to recognise Founder and CEO, Dr. Clarissa Yates, Ph.D., for her role as a featured panelist at Tech Ready Women Academy’s International Women’s Day event, An Evening with Christie Whitehill: Breaking Barriers in Capital Raising.
Ketim Technologies Secures Provisional Approval to Access ORIGINS Birth Cohort Biobank for Postpartum Depression Biomarker Validation
Brisbane, Australia – Feb 20, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to announce it has been granted provisional approval as a commercial entity to collaborate with The Kids Research Institute in Western Australia and access the ORIGINS Birth Cohort Biobank.
Ketim Therapeutics Welcomes Dr. Scott Fry, Ph.D., to Advisory Board
Ketim Therapeutics Announces New Advisory Board Member, Dr. Scott Fry, Ph.D.
Ketim Therapeutics is thrilled to welcome Dr. Scott Fry, Ph.D., to its Advisory Board. With extensive expertise in diagnostics and biotechnology, Dr. Fry’s career highlights include leading the successful launch of the first over-the-counter COVID-19 diagnostic test in the United States as Chief Operations Officer at Ellume Limited. His experience in scaling diagnostic solutions, including ELISAs for detecting various diseases, aligns perfectly with Ketim’s mission to transform perinatal mental health care.
“Dr. Fry’s strategic insights and vast experience will help us drive innovation and deliver impactful solutions for women’s health,” said Dr. Clarissa Yates, CEO of Ketim Therapeutics.
Ketim Therapeutics Appoints Dr Carrie Hillyard to Board of Directors
Ketim Therapeutics Welcomes Dr Carrie Hillyard AM to Board of Directors
Dr Carrie Hillyard AM, a trailblazer in life sciences and venture capital, joins Ketim Therapeutics' Board of Directors. With decades of experience in medical research, diagnostics, and start-up mentoring, Dr Hillyard's strategic insights will guide Ketim's mission to revolutionise maternal mental health through biomarker-driven solutions.
Ketim Therapeutics Announces the Appointment of Dr. Maciej Trzaskowski as Chief Scientific Officer
We are thrilled to announce the appointment of Dr. Maciej Trzaskowski, PhD as our new Chief Scientific Officer! His extensive background, including roles at King’s College London, QUT, and as Founder of Profenso, aligns perfectly with Ketim’s vision to transform mental health screening and therapeutic solutions. Stay tuned for what’s next as we push the boundaries of innovation together with an idea.
Ketim Therapeutics Unveils Promising Pilot Study Results in the Quest for Early Postpartum Depression Detection
Ketim Therapeutics has achieved a significant breakthrough in maternal mental health research with the successful completion of a pilot study examining blood samples from the Queensland Family Cohort Study. In collaboration with the Australian Genome Research Facility, Ketim identified an 11-protein biomarker signature linked to postpartum depression (PPD) risk, out of over 5,400 proteins screened. This finding could enable the early prediction of PPD, offering a lifeline to mothers at risk. The next phase involves validating these results in an independent birth cohort, a process already underway, bringing Ketim closer to developing a reliable, non-invasive screening tool that could transform maternal healthcare.
Ketim Therapeutics enters agreements with Mater Research
Ketim Therapeutics has partnered with Mater Research to advance predictive biomarker research for perinatal depression using Queensland Family Cohort data. Affecting 1 in 5 women, perinatal depression poses serious risks, yet early detection remains a challenge. By identifying blood-based biomarkers, Ketim’s AI-driven technology aims to equip clinicians with a powerful early detection tool for personalised care. This collaboration strengthens Ketim’s mission to bridge research and clinical application, setting a new standard for maternal mental health diagnostics.